ORTEXORTEX News
Live short interest, options flow, and signals — free on ORTEX.Sign up free →
Market Commentary

Bears Pile Into CoreWeave as Chewy Shorts Near Record

By ORTEX News · Edited by , Editor, ORTEX NewsUpdated 1 min read

Produced automatically from ORTEX data and published under the ORTEX News editorial standards set by Peter Hillerberg, Editor, ORTEX News. How we publish

ShareXLinkedInReddit

Short sellers stepped up pressure on CoreWeave this week. SI as a percentage of free float climbed to 24.8%, up from 21.2% a week ago, a rise of 3.6 percentage points. Morgan Stanley cut its price target on the AI cloud stock to $70 today, adding fuel to the bearish case.

Chewy remains one of the most-shorted large-cap names in the US market at 86.7% of free float. That is a sharp climb from 66% in early October. Days to cover stands near 2.9, and availability is unusually high at 534%, meaning plenty of stock is still available for new short positions.

Wolfspeed carries 83.8% SI of free float with nearly 10 days to cover. Zero availability signals borrow is essentially exhausted. Lucid Group sits at 64.6%, ticking up 1.9 percentage points over seven days.

Gas producer BKV Corporation saw the sharpest SI jump of the week among mid-caps. Short interest rose nearly 4 percentage points to 38.6% of free float, the highest level since the company came to market.

Tesla remains lightly shorted at just 2.65% of free float, even as commentary about Elon Musk's earnings call projections circulates widely. GameStop shorts hold 10.2% of float, steady and well off its meme-era highs.

The ORTEX Index Rebalance Radar flags Vaxcyte as a live two-way flow setup. At a $9.9bn market cap, it sits simultaneously near the Russell 1000 entry and Russell 2000 exit lines, with a 30 October cut-off approaching.

Stocks in this article

How this article was generated

Generated
23 Oct 2026, 12:02
Prompt version
v1.0
Data sources
Short interestCost to borrowUtilizationAlt DataIndex Rebalance

ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.